Drugmakers resist U.K. price goals

Drug companies are standing their ground in price negotiations with the U.K. government. Pharma is offering to cut the U.K.'s drug bill by roughly half the government's goal, The Daily Telegraph reports. Industry negotiators said they'd reduce the prices of patented drugs by less than 5 percent, when the government was reported to be seeking a 10 percent to 12 percent reduction. To make up some of the difference, drugmakers are saying they'll cut the price of drugs that come off patent but still have little generic competition.

Apparently, the negotiators are at odds over predicted increases in drug costs. Pharma is predicting just 3 percent annual growth, but the government is expecting something like 8 percent, an "insider" told the newspaper.

- read the Telegraph article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.